Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.

Related Videos
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Gary Price, MD, MBA
Veronica Villareal, MHA/MBA
Veronica Villareal, MHA/MBA
Veronica Villareal, MHA/MBA
Veronica Villareal, MHA/MBA
© 2023 MJH Life Sciences

All rights reserved.